Catalog No.
YHF65601
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
Met1-Arg180
Predicted molecular weight
30.51 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
P78358
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
LAGE2B, CTAG1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, CTAG1A, L antigen family member 2, Cancer/testis antigen 1, LAGE2A, ESO1, CTAG, LAGE-2, LAGE2, CT6.1
Phage display enables machine learning discovery of cancer antigen-specific TCRs., PMID:40498839
Stabilized iRGD modification enhances NY-ESO-1 TCR-T infiltration in solid tumors and synergizes with PD-1 blockade., PMID:40445421
In Vivo Evaluation of Pam2Cys-Modified Cancer-Testis Antigens as Potential Self-Adjuvanting Cancer Vaccines., PMID:40326329
Association Between Kita-kyushu Lung Cancer Antigen-1 Expression in Gastric Cancer and Helicobacter pylori-infection Status., PMID:40155017
Expression of Cancer-Testis Antigens MAGE-A1, MAGE-A4, NY-ESO-1 and PRAME in Bone and Soft Tissue Sarcomas: The Experience From a Single Center in China., PMID:40152485
mTOR inhibition modulates vaccine-induced immune responses to generate memory T cells in patients with solid tumors., PMID:40132910
Treatment strategies for advanced synovial sarcoma: from chemotherapy to TCR-engineered T-cell therapy., PMID:40122967
Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies., PMID:40054461
The value of serum tumor-associated autoantibodies in screening and diagnosis of gastric cancer., PMID:39900126
Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma., PMID:39836945
Generation of effective and specific human TCRs against tumor/testis antigen NY-ESO-1 in mice with humanized T cell recognition system., PMID:39776913
Decoding NY-ESO-1 TCR T cells: transcriptomic insights reveal dual mechanisms of tumor targeting in a melanoma murine xenograft model., PMID:39660132
Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non-Small Cell Lung Cancer., PMID:39576208
NY-ESO-1 antigen: A promising frontier in cancer immunotherapy., PMID:39275923
Brief Communication on MAGE-A4 and Coexpression of Cancer Testis Antigens in Metastatic Synovial Sarcomas: Considerations for Development of Immunotherapeutics., PMID:39224047
Investigating the prognostic impact of NY-ESO-1 expression and HLA subtypes in metastatic synovial sarcoma., PMID:39153316
Automated immunoassay of serum NY-ESO-1 and XAGE1 antibodies for predicting clinical benefit with immune checkpoint inhibitor (ICI) in advanced non-small cell lung cancer., PMID:38964205
Restoration of ARID1A Protein in ARID1A-deficient Clear Cell Carcinoma of the Ovary Attenuates Reactivity to Cytotoxic T Lymphocytes., PMID:38944423
Expression of the tumor antigens NY-ESO-1, tyrosinase, MAGE-A3, and TPTE in pediatric and adult melanoma: a retrospective case control study., PMID:38890171
Epigenetic Induction of Cancer-Testis Antigens and Endogenous Retroviruses at Single-Cell Level Enhances Immune Recognition and Response in Glioma., PMID:38856710
Multiplex genetic manipulations in Clostridium butyricum and Clostridium sporogenes to secrete recombinant antigen proteins for oral-spore vaccination., PMID:38659027
Comprehensive multiplexed autoantibody profiling of patients with advanced urothelial cancer., PMID:38309723
EGFR, HLA-G, CD70, c-MET, and NY-ESO1 as potential biomarkers in high grade epithelial ovarian carcinoma., PMID:38250760
The role of the NY-ESO-1 in the prognosis of gastric cancer., PMID:38153439
Gene of the month: cancer testis antigen gene 1b (NY-ESO-1)., PMID:37857483
Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer., PMID:37634036
Expression and Prognostic Significance of PD-L1 and NY-ESO1 in Gallbladder Carcinoma., PMID:37369470
Novel diagnostic biomarkers of T cell-mediated tumor killing characteristics for early-stage triple negative breast cancer: A SEER analysis and molecular portraits., PMID:36827041
Combinational expression of tumor testis antigens NY-ESO-1, MAGE-A3, and MAGE-A4 predicts response to immunotherapy in mucosal melanoma patients., PMID:36527482
NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome., PMID:35768164
Clinicopathological assessment of cancer/testis antigens NY‑ESO‑1 and MAGE‑A4 in osteosarcoma., PMID:35736245
Cancer-Testis Gene Biomarkers Discovered in Colon Cancer Patients., PMID:35627192
Efficient targeting of NY-ESO-1 tumor antigen to human cDC1s by lymphotactin results in cross-presentation and antigen-specific T cell expansion., PMID:35428705
[Ⅱ. NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Sarcoma Patients]., PMID:35299181
Cancer immunotherapy using artificial adjuvant vector cells to deliver NY-ESO-1 antigen to dendritic cells in situ., PMID:34971473
Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy., PMID:34933966
Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β., PMID:34853077
Expression of CTAG1B clone EPR13780 versus DDIT3 gene rearrangement distinguishes myxoid liposarcoma from its mimics with detection of novel DDIT3 gene copy number variations., PMID:34845972
Integration of IgG and IgA autoantibodies for early diagnosis of hepatocellular carcinoma., PMID:34728178
Targeting cancer testis antigens in synovial sarcoma., PMID:34083416
Reverse Vaccinology Approach in Constructing a Multi-Epitope Vaccine Against Cancer-Testis Antigens Expressed in Non-Small Cell Lung Cancer., PMID:34048178
IL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapy., PMID:33963013
Backbone Modifications of HLA-A2-Restricted Antigens Induce Diverse Binding and T Cell Activation Outcomes., PMID:33881854
Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients., PMID:33751208
Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells., PMID:33466646
Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer., PMID:33458968
Specific Inhibition of Tumor Growth by T Cell Receptor-Drug Conjugates Targeting Intracellular Cancer-Testis Antigen NY-ESO-1/LAGE-1., PMID:33237767
Leveraging Automation toward Development of a High-Throughput Gene Expression Profiling Platform., PMID:32935608
[Integrated bioinformatics analysis of key genes in allergic rhinitis]., PMID:32842359
HLA Genotyping in Synovial Sarcoma: Identifying HLA-A*02 and Its Association with Clinical Outcome., PMID:32816945
For research use only. Not for human or drug use.
